NervGen Pharma Corp.
NervGen Pharma Corp. (NGENF) Financial Performance & Income Statement Overview
Explore the financials of NervGen Pharma Corp. (NGENF), including yearly and quarterly data on income, cash flow, and balance sheets.
NervGen Pharma Corp. (NGENF) Income Statement & Financial Overview
View the income breakdown for NervGen Pharma Corp. NGENF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $15028.00 | $38306.00 |
| Gross Profit | $0.00 | $0.00 | -$15028.00 | -$38306.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $4.59M | $4.36M | $3.80M | $3.00M |
| SG&A Expenses | $2.21M | $2.79M | $2.20M | $2.00M |
| Operating Expenses | $6.81M | $7.16M | $5.99M | $5.00M |
| Total Costs & Expenses | $6.81M | $7.16M | $6.000M | $5.00M |
| Interest Income | $171110.00 | $243679.00 | $294879.00 | $102949.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $15810.00 | $14652.00 | $15029.00 | $38306.00 |
| EBITDA | -$6.79M | -$7.14M | -$5.99M | -$4.95M |
| EBITDA Ratio | ||||
| Operating Income | -$6.81M | -$7.16M | -$6.000M | -$5.00M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | -$1.80M | $1.93M | -$1.83M | $2.62M |
| Income Before Tax | -$8.61M | -$5.23M | -$7.83M | -$2.35M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $2.30M |
| Net Income | -$8.61M | -$5.23M | -$7.83M | -$2.30M |
| Net Income Ratio | ||||
| EPS | -$0.12 | -$0.07 | -$0.11 | -$0.04 |
| Diluted EPS | -$0.12 | -$0.07 | -$0.11 | -$0.04 |
| Weighted Avg Shares Outstanding | $70.07M | $70.07M | $69.95M | $60.21M |
| Weighted Avg Shares Outstanding (Diluted) | $70.07M | $70.07M | $69.95M | $60.21M |
Over the last four quarters, NervGen Pharma Corp. achieved steady financial progress, growing revenue from $0.00 in Q1 2024 to $0.00 in Q4 2024. Gross profit stayed firm with margins at N/A in Q4 2024 versus N/A in Q1 2024. Operating income totaled -$6.81M in Q4 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$6.79M. Net income dropped to -$8.61M, with EPS at -$0.12. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan